Patent news

USPTO upheld the validity of Osteotech patent on radiolucent material
Osteotech, Inc. , a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Patent and Trademark Office has confirmed the validity of its US5,676,146. The '146 patent covers mixtures of a radiolucent material, such as demineralized bone, with a radiopaque material, such as nondemineralized or partially demineralized bone, that is provided in sufficient quantity to be used as a radiographic marker. The Patent Office's reexamination certificate also includes four new claims.
Neptune got patent on Natural Marine Source Phospholipids
Neptune Technologies & Bioressources Inc. announces that the European Patent Office (EPO) granted on May 31st 2007 Neptune's composition of matter patent EP01417211 entitled "Natural Marine Source Phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications" and that this patent has now been issued and validated in twenty-four European countries.
Epeius Biotechnologies got patent on Targeted gene delivery
Epeius Biotechnologies announced today the issue of US7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.
Human Genome Hits Genentech With Patent Suit
A patent dispute between two biotechnology companies over a type of protein that can be used to detect tumors has landed in federal court, after Human Genome Sciences appealed the USPTO decision in an interference proceeding.
Invitrogen Sues GE for Enzyme Kit Patent infringement
Invitrogen sue GE health care subsidiary with two lawsuits alleging that GE is willfully infringing several patents related to reverse transcriptase enzyme kits and DNA amplification kits.